4025 Sorrento Valley Boulevard
United States - Map
Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies for treating a range of human diseases primarily in the United States. The companys lead product candidate includes iSONEP, a monoclonal antibody against sphingosine-1-phosphate (S1P), which has completed Phase I clinical trials to treat wet age-related macular degeneration; and is in Phase 1b/2a clinical trials to treat retinal pigment epithelium detachment. Its products under development also comprise ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid S1P that is in Phase 2a clinical trials for the treatment for renal cell carcinoma; various forms of cancer; and other angiogenic-related and inflammatory-oriented indications. In addition, the company is developing Lpathomab, a mAb against lysophosphatidic acid, which is in pre-clinical trials intended for the treatment of neuropathic pain, traumatic brain injury, spinal cord injury, and fibrosis cancer. It has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.
|Mr. Scott R. Pancoast ,
Founder, Chief Exec. Officer, Pres, Director and Member of R & D Advisory Committee
|Mr. Gary J. G. Atkinson ,
Chief Financial Officer, Principal Accounting Officer, VP and Sec.
|Dr. Gary Woodnutt Ph.D.,
Sr. VP of Research
|Dr. Dario A. Paggiarino M.D.,
Chief Devel. Officer and Sr. VP
|Mr. Roger A. Sabbadini Ph.D.,
Scientific Founder and VP
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|